
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Ju Fu Tang Biotech Holdings Co., Ltd**, you should at once hand this circular and the enclosed proxy form to the purchaser or transferee or to the bank, stockbroker or other agents through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

Ju Fu Tang Biotech Holdings Co., Ltd

菊福堂生物控股有限公司

(formerly known as “WMHW Holdings Limited 萬民好物控股有限公司”)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8217)

**PROPOSAL FOR RE-ELECTION OF DIRECTOR
AND
SUPPLEMENTAL NOTICE OF
THE ANNUAL GENERAL MEETING**

This supplemental circular should be read together with the circular of the Company dated 31 July 2026. A supplemental notice convening the annual general meeting of Ju Fu Tang Biotech Holdings Co., Ltd to be held at Portion 2, 12/F, The Center, 99 Queen’s Road Central, Central, Hong Kong on Thursday, 10 September 2026 at 11:00 a.m. is set out in this supplemental circular. A revised form of proxy for use at the Annual General Meeting is enclosed. Such revised form of proxy is also published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at <https://www.todayir.com/irshowcase/8217>.

Whether or not you are able to attend the meeting, you are requested to complete and return the enclosed revised form of proxy in accordance with the instructions printed thereon as soon as possible and in any event not less than 48 hours before the time fixed for holding the Annual General Meeting or any adjournment thereof. Completion and return of the revised form of proxy will not preclude you from attending and voting at the Annual General Meeting or any adjourned meeting if you so wish.

21 August 2026

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	3
Appendix – Details of Director proposed to be re-elected at the AGM	7
Supplemental Notice of AGM	8

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

“AGM”	the annual general meeting of the Company to be convened and held at Portion 2, 12/F, The Center, 99 Queen’s Road Central, Central, Hong Kong on 10 September 2026 (Thursday) at 11:00 a.m., the notice of which is set out on pages 14 to 18 of the circular of the Company dated 31 July 2026 and the supplemental notice of which is set out on page 8 of this circular
“associate(s)”	has the same meaning ascribed to it under the GEM Listing Rules
“Board”	the board of Directors
“close associate(s)”	has the same meaning ascribed to it under the GEM Listing Rules
“Company”	Ju Fu Tang Biotech Holdings Co., Ltd, a company incorporated in the Cayman Islands with limited liability on 16 October 2015, the Shares of which are listed on GEM of the Stock Exchange
“connected person(s)”	has the same meaning ascribed to it under the GEM Listing Rules
“controlling shareholder(s)”	has the same meaning ascribed to it under the GEM Listing Rules
“core connected person(s)”	has the same meaning ascribed to it under the GEM Listing Rules
“Director(s)”	the director(s) of the Company
“GEM”	the GEM of the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China

DEFINITIONS

“Issue Mandate”	a general and unconditional mandate proposed to be granted to the Directors to exercise all power of the Company to allot, issue and otherwise deal with Shares of up to 20% of the aggregate number of issued share of the Company as at the date of AGM as set out in resolution number 4 of the AGM Notice
“Latest Practicable Date”	18 August 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained herein
“Listing Date”	12 April 2016, being the date of listing of the Shares on GEM
“Memorandum and Articles of Association”	the memorandum and articles of association of the Company, as amended from time to time
“Options”	the options granted under the Share Option Scheme to subscribe for Shares in accordance with the terms thereof
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong), as amended and supplemented from time to time
“Shares”	ordinary share(s) with nominal value of HK\$0.16 each in the share capital of the Company
“Shareholder(s)”	the holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”	has the same meaning ascribed to it under the GEM Listing Rules
“%”	per cent.

LETTER FROM THE BOARD

Ju Fu Tang Biotech Holdings Co., Ltd

菊福堂生物控股有限公司

(formerly known as “WMHW Holdings Limited 萬民好物控股有限公司”)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8217)

Executive Directors:

Mr. Chen Jian

Ms. Yu Xiao

Independent non-executive Directors:

Mr. Wong Chi Kan

Ms. Lao In Iam

Ms. Wong Mei Yin Mian

Registered Office:

P.O. Box 1350 Clifton House

75 Fort Street

Grand Cayman KY1-1108

Cayman Islands

*Headquarters and Principal Place
of Business in Hong Kong:*

Unit 2202, 22/F,

Causeway Bay Plaza I,

489 Hennessy Road,

Causeway Bay

Hong Kong

21 August 2026

To the Shareholders

Dear Sirs/Madams,

PROPOSAL FOR RE-ELECTION OF DIRECTOR AND SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

INTRODUCTION

This supplemental circular should be read together with the circular of the Company dated 31 July 2026 which contains, among other things, information regarding the resolutions to be proposed at the Annual General Meeting. The purpose of this supplemental circular is to give you the supplemental notice of the Annual General Meeting and provide you with further information regarding the resolutions to be proposed at the Annual General Meeting for approving the re-election of Director.

LETTER FROM THE BOARD

RE-ELECTION OF RETIRING DIRECTOR

Subsequent to the despatch of the circular and the notice of the annual general meeting, the composition of the Board and committees of the Board has changed as follows:

1. On 17 August 2026, Mr. Liao Honghao (“**Mr. Liao**”) resigned as an independent non-executive Director, and a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee;
2. On 17 August 2026, Ms. Wong Mei Yin Mian (“**Ms. Wong**”) was appointed as an independent non-executive Director and a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.

For further details of the above, please refer to the announcement of the Company dated 17 August 2026.

In accordance with article 112 of the Articles of Association, any Director appointed by the Board to fill a casual vacancy shall hold office until the next following annual general meeting of the Company after her appointment and shall then be eligible for re-election and any Director appointed by the Board as an addition to the existing Board shall hold office only until the next following annual general meeting of the Company and shall then be eligible for re-election. Accordingly, Ms. Wong who was newly appointed by the Board on 17 August 2026 shall retire from office and offer herself for re-election at the Annual General Meeting.

As at the date of this announcement, the executive Directors are Mr. Chen Jian and Ms. Yu Xiao and the independent non-executive Directors are Mr. Wong Chi Kan, Ms. Wong Mei Yin Mian and Ms. Lao In Iam.

In view of the above, the new ordinary resolution in respect of re-election of Ms. Wong as an independent non-executive Director will be submitted to the Shareholders for consideration and approval at the Annual General Meeting.

The Directors consider that the resolution as set out in the supplemental notice of the Annual General Meeting is in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions at the Annual General Meeting.

The brief biographical and other details of Ms. Wong are set out in the Appendix to this supplemental circular.

LETTER FROM THE BOARD

THE AGM AND REVISED FORM OF PROXY

Set out on page 8 of this supplemental circular is a supplemental notice convening the Annual General Meeting to consider and, if appropriate, to approve, among others, the newly added ordinary resolution relating to the proposal for the re-election of Director.

A revised form of proxy for use by Shareholders at the AGM is enclosed with this circular. Whether or not you intend to attend and vote at the AGM in person, you are requested to complete and return the enclosed revised form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof (as the case may be). Completion and return of the revised form of proxy will not preclude you from subsequently attending and voting in person at the AGM or any adjournment thereof (as the case may be) should you so desire. If you have not yet deposited the form of proxy attached to the circular of the Company dated 31 July 2026 (the **"Original Form of Proxy"**), you are requested to deposit only the revised form of proxy if you intend to appoint a proxy to attend the AGM on your behalf. Any Shareholder who has already deposited the Original Form of Proxy should note that:

- (i) if the revised form of proxy is deposited before the Closing Time, the revised form of proxy will revoke and supersede the Original Form of Proxy previously deposited by the Shareholder. The revised form of proxy (if duly completed) will be treated as a valid form of proxy deposited by the Shareholder; and
- (ii) if no revised form of proxy is deposited before the Closing Time, the Original Form of Proxy (if duly completed) will be treated as a valid form of proxy deposited by the Shareholder. The proxy so appointed pursuant to the Original Form of Proxy will be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her discretion (if no such instructions are given) on any resolution properly put to the Annual General Meeting, including the newly added ordinary resolution as set out in the supplemental notice of the AGM.

Apart from the new ordinary resolution and other information as set out in this supplemental circular, all other matters to be dealt with at the AGM remain unchanged. For details of other resolutions to be considered and approved at the AGM and other relevant matters, please refer to the circular of the Company dated 31 July 2026.

LETTER FROM THE BOARD

VOTING AT THE AGM

Pursuant to Rule 17.47(4) of the GEM Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands.

On a poll, every Shareholder present in person or by proxy or in the case of a Shareholder being a corporation, by its duly authorised representative shall have one vote for each share registered in his/her name in the register. A Shareholder entitled to more than one vote needs not use all his/her votes or cast all the votes he/she uses in the same way.

RECOMMENDATION

The Directors consider that the newly added ordinary resolution in relation to the re-election of Director as set out in the supplemental notice of the AGM are in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions at the AGM.

To the best knowledge of the Directors, no Shareholders will have to abstain from voting at the AGM.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

By order of the Board
Ju Fu Tang Biotech Holdings Co., Ltd
Chen Jian
Executive Director

The following are particulars of the Directors proposed to be re-elected at the AGM:

RE-ELECTION OF DIRECTOR**Ms. Wong Mei Yin Mian (“Ms. Wong”)**

Ms. Wong, aged 55, has engaged in the corporate governance industry for over 20 years.

She has extensive experience in corporate governance frameworks, internal control reviews, pre-IPO compliance, risk oversight and fraud prevention across multi-jurisdictional entities.

Ms. Wong obtained Master of Business Administration and a Bachelor of Arts (Honours) in Accounting and Finance from The Chinese University of Hong Kong and University of Glamorgan, U.K. respectively. She is also a fellow member of the Hong Kong Institute of Certified Public Accountants, fellow member of Association of Chartered Certified Accountants, certified internal auditor of The Institute of Internal Auditors. Ms. Wong was appointed as independent non-executive director on 17 August 2026.

Ms. Wong has entered into a letter of appointment with the Company for a term of three years. In accordance with the Articles of Association, Ms. Wong is subject to retirement by rotation and re-election at the Company’s general meetings. The director’s fee of Ms. Wong is HK\$120,000 per annum, which was determined with reference to her duties and responsibilities with the Company.

Save as disclosed above, Ms. Wong does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, Ms. Wong has confirmed that she does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company (within the meaning of the GEM Listing Rules).

As at the Latest Practicable Date, she has no interests in the Shares which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Company considers that in relation to the re-election of Ms. Wong as an independent non-executive Director, there is no information to be disclosed pursuant to paragraphs (h) to (v) of Rule 17.50(2) of the GEM Listing Rules and there are no other matters that needs to be brought to the attention of the Shareholders.

SUPPLEMENTAL NOTICE OF AGM

Ju Fu Tang Biotech Holdings Co., Ltd

菊福堂生物控股有限公司

(formerly known as “WMHW Holdings Limited 萬民好物控股有限公司”)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8217)

This supplemental notice is supplemental to the notice of the annual general meeting (the “AGM”) of Ju Fu Tang Biotech Holdings Co., Limited (the “Company”) dated 31 July 2026 (the “Original Notice”) to convene the AGM to be held on Thursday, 10 September 2026, at 11:00 a.m. at Portion 2, 12/F, The Center, 99 Queen’s Road Central, Central, Hong Kong. Unless otherwise specified, capitalised terms used in this supplemental notice shall have the same meanings as those defined in the Original Notice.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT:

Due to the matters as set out in the supplemental circular of the Company dated 21 August 2026 (the “Supplemental Circular”), the following resolution in addition to the resolutions as set out in the Original Notice will also be considered and, if thought fit, with or without amendments, as ordinary resolution of the Company:

7. To re-elect Ms. Wong Mei Yin Mian as an independent non-executive director of the Company.

Apart from the amendments set out above, all the information contained in the Original Notice shall remain to have full force and effect.

By order of the Board
Ju Fu Tang Biotech Holdings Co., Ltd
Chen Jian
Executive Director

Hong Kong, 21 August 2026

Notes:

1. Details of the resolution stated above are set out in the Supplemental Circular. A revised form of proxy containing, among others, the above resolution is enclosed with the Supplemental Circular. Please refer to the section headed “The AGM and Revised Form of Proxy” on page 5 of the Supplemental Circular for arrangements on the completion and submission of the revised form of proxy.
2. Apart from the newly added resolution and other information as set out in the Supplemental Circular, all other matters to be dealt with at the Annual General Meeting remain unchanged. For details of the other resolutions to be considered and approved at the AGM, eligibility for attending/voting at the AGM, closure of register of members of the Company and other relevant matters, please refer to the circular of the Company dated 31 July 2026.